United Therapeutics (UTHR) Convertible Debt (2011 - 2013)

United Therapeutics has disclosed Convertible Debt across 3 years of filings, most recently posting $207.4 million for Q1 2013.

• Convertible Debt for Q1 2013 came in at $207.4 million, up 5.41% year-over-year; the trailing twelve-month figure through Mar 2013 was $207.4 million (up 5.41% YoY), and the FY2012 annual result was $204.7 million, up 5.4% from the prior year.
• Convertible Debt came in at $207.4 million for Q1 2013 at United Therapeutics, up from $204.7 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $207.4 million in Q1 2013 to a low of $194.2 million in Q4 2011.
• The 3-year median for Convertible Debt is $200.7 million (2012), against an average of $200.7 million.
• Across the five-year window, Convertible Debt climbed 5.4% in 2012 and climbed 5.41% in 2013, its largest moves.
• United Therapeutics' Convertible Debt stood at $194.2 million in 2011, then climbed by 5.4% to $204.7 million in 2012, then advanced by 1.33% to $207.4 million in 2013.
• The last three Convertible Debt figures came in at $207.4 million (Q1 2013), $204.7 million (Q4 2012), and $202.0 million (Q3 2012), per Business Quant data.